Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysisGiuseppe Di Lorenzo, Sabino De Placido, Riccardo Autorino et al.|Annals of Oncology|2009Cited by 205
The Society for Immunotherapy of Cancer perspective on regulation of interleukin-6 signaling in COVID-19-related systemic inflammatory responseFernanda I. Arnaldez, Paolo A. Ascierto, Haiming Wei et al.|Journal for ImmunoTherapy of Cancer|2020Cited by 93
Impact of COVID-19 outbreak on cancer immunotherapy in Italy: a survey of young oncologistsMargaret Ottaviano, Vincenzo Montesarchio, Marcello Curvietto et al.|Journal for ImmunoTherapy of Cancer|2020Cited by 19
Abstract P6-21-13: A phase II single arm trial evaluating the efficacy and safety of eribulin in combination with bevacizumab for second-line treatment of human epidermal growth factor receptor 2 (HER2)–negative metastatic breast cancer (MBC) progressing after first-line therapy with bevacizumab and paclitaxelSabino De Placido, Grazia Arpino, Michelino De Laurentiis et al.|Cancer Research|2019Cited by 0